Resonant Capital Advisors LLC Invests $267,000 in Novartis AG (NYSE:NVS)

Resonant Capital Advisors LLC bought a new position in Novartis AG (NYSE:NVS) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,817 shares of the company’s stock, valued at approximately $267,000.

Several other large investors have also recently bought and sold shares of the stock. West Bancorporation Inc. purchased a new stake in Novartis during the fourth quarter valued at $26,000. Atlas Private Wealth Management bought a new stake in shares of Novartis in the 4th quarter worth about $26,000. Tsfg LLC increased its holdings in shares of Novartis by 94.3% in the 4th quarter. Tsfg LLC now owns 309 shares of the company’s stock worth $29,000 after buying an additional 150 shares during the last quarter. Cedar Mountain Advisors LLC purchased a new stake in shares of Novartis during the 4th quarter valued at about $29,000. Finally, PSI Advisors LLC bought a new position in shares of Novartis in the 4th quarter valued at about $32,000. Institutional investors own 11.20% of the company’s stock.

Shares of NVS stock traded up $2.85 during trading hours on Thursday, reaching $79.74. 2,677,631 shares of the stock were exchanged, compared to its average volume of 2,806,302. The firm has a market capitalization of $168.58 billion, a price-to-earnings ratio of 15.79, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. Novartis AG has a 12-month low of $69.18 and a 12-month high of $99.84. The company’s 50-day moving average price is $87.35 and its 200-day moving average price is $89.80. The company has a current ratio of 1.04, a quick ratio of 0.83 and a debt-to-equity ratio of 0.40.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $1.31 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.32 by ($0.01). Novartis had a return on equity of 23.39% and a net margin of 24.73%. The firm had revenue of $12.40 billion during the quarter, compared to analysts’ expectations of $12.49 billion. On average, sell-side analysts expect that Novartis AG will post 5.74 EPS for the current year.

The firm also recently declared an annual dividend, which was paid on Thursday, March 12th. Stockholders of record on Wednesday, March 4th were issued a $3.0425 dividend. This represents a dividend yield of 2%. This is an increase from Novartis’s previous annual dividend of $2.86. The ex-dividend date was Tuesday, March 3rd. Novartis’s dividend payout ratio is presently 38.36%.

Several brokerages have weighed in on NVS. Citigroup cut Novartis from a “buy” rating to a “neutral” rating in a research note on Monday, February 17th. Guggenheim cut Novartis from a “buy” rating to a “neutral” rating in a report on Tuesday, February 25th. Finally, Morgan Stanley upgraded Novartis from an “underweight” rating to an “equal weight” rating in a report on Tuesday, March 10th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. Novartis has a consensus rating of “Hold” and an average target price of $93.34.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Further Reading: What is a stock portfolio tracker?

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with's FREE daily email newsletter.